linjc16/ctgov huggingface dataset:
To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC

Study Overview
=================
Brief Summary
-----------------
Evaluated the correlation between the qualitative test results of Xiamen Aide the gene test specified by the test reagent and the efficacy of relevant targeted drugs in patients with non-small cell lung cancery, and the research data is used to support the registration and marketing of the assessment reagent

Official Title
-----------------
To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)

Conditions
-----------------
Non Small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1)≥18; 2) advanced non-small cell lung cancer confirmed by histopathology; 3) Patients with NSCLC who have previously or are taking gefitinib (first-line therapy) or osimertinib (post-TKI resistance) or crizotinib monotherapy, and the response to treatment can be assessed; 4) Have sufficient FFPE tissue samples within 5 years: 5 large specimens/case; There were 10 puncture specimens/case Exclusion Criteria: 1) Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs; 2)Maintenance therapy if the disease does not progress after treatment with other antitumor methods

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first) | 2 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ORR | Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects | 2 years |
Study of the Feasibility of Early Lung Ultrasound in Neonatal Respiratory Distress in Premature Newborns Born Between 32 Weeks of Amenorrhea and 36 Weeks Plus 6 Days of Amenorrhea, Hospitalized in the Neonatal Pediatrics and Intensive Care Units of the Dijon University Hospital

Study Overview
=================
Brief Summary
-----------------
Monocentric study carried out in the Neonatal and Intensive Care Units of the Dijon University Hospital. The objective is to evaluate the feasibility of performing a pulmonary ultrasound within 6 hours after admission in premature infants born between 32 weeks of amenorrhea and 36 weeks of amenorrhea + 6 days who are hospitalized for initial respiratory distress. Pulmonary ultrasound is performed within 6 hours of admission and an ultrasound score is calculated according to the images observed. Continued management according to protocols without taking into account the ultrasound data. Follow-up of patients until discharge from hospital or D28 of life (whichever comes first)

Official Title
-----------------
Study of the Feasibility of Early Lung Ultrasound in Neonatal Respiratory Distress in Premature Newborns Born Between 32 Weeks of Amenorrhea and 36 Weeks Plus 6 Days of Amenorrhea, Hospitalized in the Neonatal Pediatrics and Intensive Care Units of the Dijon University Hospital

Conditions
-----------------
Neonatal Respiratory Distress, Preterm Birth

Intervention / Treatment
-----------------
* Procedure: Pulmonary ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Verbal consent from at least one legal guardian Premature infant (between 32 weeks of amenorrhea and 36 weeks of amenorrhea + 6 days) admitted for neonatal respiratory distress that began in the first 2 hours of life Hospitalized at the Dijon University Hospital in the Neonatal Pediatrics and Intensive Care Units Exclusion Criteria: individual is not affiliated to the national health care system major intrathoracic or abdominal malformation

Ages Eligible for Study
-----------------
Minimum Age: 0 Hours
Maximum Age: 2 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Premature infants<br>premature infants born between 32 and 36 weeks of amenorrhea + 6 days hospitalized for respiratory distress | Procedure: Pulmonary ultrasound<br>* Within 6 hours of admission to Neonatal Pediatrics and Intensive Care<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of infants receiving a lung ultrasound within 6 hours of admission divided by the number of infants meeting the inclusion criteria | Number of infants receiving a lung ultrasound within 6 hours of admission divided by the number of infants meeting the inclusion criteria | Within 6 hours of admission |
Treatment of Atrial Fibrillation in the Community Settings

Study Overview
=================
Brief Summary
-----------------
Description of treatment of cardiovascular diseases in community settings in Russia

Detailed Description
-----------------
The study will describe different treatment modalities used in management of cardiovascular diseases in community hospital in small town of Tarusa in Russia. This part of the study will focus on atrial fibrillation and its treatment.

Official Title
-----------------
Treatment of Atrial Fibrillation in the Community Settings

Conditions
-----------------
Atrial Arrhythmia, Cardiovascular Diseases

Intervention / Treatment
-----------------
* Procedure: Direct current cardioversion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients undergoing direct current cardioversion for atrial fibrillation or flutter Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with atrial fibrillation<br>Direct current cardioversion | Procedure: Direct current cardioversion<br>* Direct current cardioversion to maintain sinus rhythm during rhythm control strategy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Restoration of sinus rhythm | Restoration of sinus rhythm during direct current cardioversion | 1 day | 
| Maintenance in rhythm control strategy | Maintenance in rhythm control strategy during treatment of atrial fibrillation | 7 years |
Compassionate Use of Vidutolimod

Study Overview
=================
Brief Summary
-----------------
Provide Compassionate Use of Vidutolimob

Detailed Description
-----------------
Compassionate use is only available to patients who transitioned from a previous vidutolimod (CMP-001) study.

Intervention / Treatment
-----------------
* Drug: Vidutolimod


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vidutolimod|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
LUng voluMe reductIoN by DuAl ENergy CT Evaluation (LUMINANCE) Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to see if a special CT scan (dual-energy CT) provides useful information in patients undergoing bronchsoscopic lung volume reduction (valve placement for emphysema). The investigators will enroll up to 30 participants in this study from University Hospitals Cleveland Medical Center. All of the participants from this study will undergo their valve procedure at University Hospitals Cleveland Medical Center.

Official Title
-----------------
LUng voluMe reductIoN by DuAl ENergy CT Evaluation (LUMINANCE) Study

Conditions
-----------------
Lung Perfusion

Intervention / Treatment
-----------------
* Procedure: Dual Energy CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (≥ 18 years of age at the time of written informed consent) with emphysema who have been deemed appropriate candidates for bronchoscopic lung volume reduction Exclusion Criteria: Patients unable to provide consent Patients who are pregnant or nursing Women of child-bearing age will undergo pregnancy tests based on University Hospital (UH) standard bronchoscopy pre-procedural testing Patients unable to undergo a DECT chest (contraindications to a CT chest with intravenous contrast such as a reported or documented allergy to intravenous (IV) contrast or impaired renal function, defined as the following: Glomerular filtration rate (GFR) <90 ml/min/1.73 m2 at the time of initial evaluation if patient age is ≤ 59 years GFR <85 ml/min/1.73 m2 if patient age is 60-69 years GFR <75 ml/min/1.73 m2 if patient age is ≥70 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients being evaluated for bronchoscopic lung volume reduction (BLVR).<br> | Procedure: Dual Energy CT<br>* Patient will receive Dual Energy CT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in lung perfusion as measured by duel-energy computed tomography |  | Baseline, 8 weeks | 
| Change in walk distance as measured by six-minute walk test |  | Baseline, 8 weeks | 
| Change in FEV1 as measured by pulmonary function test |  | Baseline, 8 weeks |
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients

Study Overview
=================
Brief Summary
-----------------
This is a randomized single-blind feasibility trial to test the utilization of home blood pressure devices to improve the clinical management of decompensated cirrhosis patients.

Detailed Description
-----------------
This is a feasibility trial to determine the feasibility of using home monitoring devices (e.g. blood pressure cuffs) to improve outcomes for cirrhosis patients.

Official Title
-----------------
Wireless Automated Tracking in Cirrhosis Patients at Home (WATCH) Trial: A Randomized Single Blind Trial Testing the Use of Home Monitoring Among Decompensated Cirrhosis Patients

Conditions
-----------------
Cirrhosis, Liver, Portal Hypertension, Ascites Hepatic

Intervention / Treatment
-----------------
* Device: Withings Home Blood Pressure Device and Scale
* Other: Standard of Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will need to have decompensated cirrhosis defined as a Child Pugh Score ≥ 7 Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: Standard of Care<br>This arm will receive a home blood pressure monitor and scale; however, these data will not be shared with their treating provider in real-time. | Other: Standard of Care<br>* Standard of Care<br>|
| Experimental: Home Blood Pressure and Scale Monitoring to Inform Clinical Decisions<br>This arm will receive a home blood pressure monitor and scale. These data will be reviewed weekly and these data will be shared with the treating provider to inform clinical decisions. | Device: Withings Home Blood Pressure Device and Scale<br>* The intervention will be whether the data generated from home monitoring devices are shared with the clinical providers. The investigators are not testing the efficacy of these approved devices.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Mean Arterial Pressure | The investigators will compare the change in mean arterial pressure before and after utilization of the data generated from the home monitoring. | Baseline and 24 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Ascites Burden | The investigators will compare the change in ascites burden, defined as the total volume of ascites removed during the study period, before and after utilization of the data generated from the home monitoring. | Baseline and 24 Weeks |
Role of Aortic Valve Composition in Pathophysiology and Diagnosis of Aortic Stenosis

Study Overview
=================
Brief Summary
-----------------
The study aims to evaluate composition differences of aortic valves in different stages and phenotypes of aortic stenosis using non-invasive imaging and histology.

Official Title
-----------------
Role of Aortic Valve Composition in Pathophysiology and Diagnosis of Aortic Stenosis

Conditions
-----------------
Aortic Stenosis, Aortic Valve Disease, Aortic Valve Calcification

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aortic valve replacement or heart transplant as part of standard care decided by the local Heart Team pre-surgical computed tomography angiography informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Severe Aortic Stenosis - High Flow, High Gradient<br>patients undergoing surgical aortic valve replacement for severe AS | |
| Severe Aortic Stenosis - classical Low Flow, Low Gradient<br>patients undergoing surgical aortic valve replacement for severe AS | |
| Severe Aortic Stenosis - paradoxical Low Flow, Low Gradient<br>patients undergoing surgical aortic valve replacement for severe AS | |
| Moderate Aortic Stenosis<br>patients undergoing aortic root replacement (Bentall procedure) | |
| Heart Transplant<br>patients undergoing orthotopic heart transplant for any reason | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aortic valve tissue composition measured from pre-procedural computed tomography angiography | Quantitative analysis of aortic valve composition will be based on pre-surgical planning CTA images using semi-automated software (Autoplaque version 2.5, Cedars-Sinai Medical Center, Los Angeles, CA, USA) for calcified, non-calcified and total tissue volumes. | up to 30-days before surgery | 
| Aortic valve tissue composition measured from quantitative histology | Different stains will be used to characterize composition of excised aortic valves (hematoxylin and eosin, Movat Pentachrome, Van Gieson's trichrome, Congo Red, anti-CD68 antibody | immediately post-surgery |
Comitial Prophylaxis in Neurosurgery in Patients Who Have Undergone Intracranial Surgery Programmed Supratentorial Surgery (Exeresis or Biopsy) Between 2019 and 2022

Study Overview
=================
Brief Summary
-----------------
JUSTIFICATION Anti-epileptic prophylaxis has long been a systematic practice for supra-tentorial intracranial surgeries. Since 2021, European guidelines no longer recommend this prophylaxis and practices have evolved. We therefore propose to compare epileptic seizure's occurrence in the first postoperative month between two groups of neurosurgical patients.The first group consists of patients treated between January 2019 and late 2020 who were given systematic prophylaxis. Patients from the second group were treated between 2021 and 2022 and did not receive any prophylaxis. The secondary objective will consist in identifying the number of patients placed on prophylaxis, the length of prophylaxis, treatment's side effects (depression, elevated liver enzymes…), and comparing patients' neurological outcome at 3 and 6 months after surgical procedures.

Official Title
-----------------
Comitial Prophylaxis in Neurosurgery in Patients Who Have Undergone Intracranial Surgery Programmed Supratentorial Surgery (Exeresis or Biopsy) Between 2019 and 2022

Conditions
-----------------
Anti-epileptic Prophylaxis in Intracranial Neurosurgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults over 18 years old Expressed non-opposition Patient who underwent supratentorial intracranial surgery (either resection or biopsy) at Brest University Hospital from January 01, 2019 to September 01, 2022. Exclusion Criteria: Refusal to participate Patient under legal protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Anti-epileptic prophylaxis<br>The first group consists of patients treated between January 2019 and late 2020 who were given systematic prophylaxis | |
| NO Anti-epileptic prophylaxis<br>Patients from the second group were treated between 2021 and 2022 and did not receive any prophylaxis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of epileptic seizures during the first postoperative month (between D-0 and D-30) of neurosurgery patients treated for elective supratentorial intracranial procedures. |  | the first postoperative month (between D-0 and D-30) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Commencement of anti-epileptic treatment Length of prophylaxis Treatment's side effects Neurological outcome at 3 and 6 months (RANKIN modified score) |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anti-epileptic prophylaxis, intracranial neurosurgery, epileptic seizures
Retrospective Study on Perioperative Safety and Quality Control Based on Real World Data

Study Overview
=================
Brief Summary
-----------------
Based on the data from the anesthesia record electronic system, patient safety incident (PSI) electronic reporting system and related PSI retrospective cohort in the past 10 years, this project intends to carry out structured and consistent (real world data)RWD processing, and conduct (real world evidence)RWE research related to perioperative safety and quality control in order to characterize the epidemiology of perioperative PSIs, explore the related factors, and construct a prediction model, and on the basis of which to construct a standardized platform for reporting and analysis of perioperative PSIs based on RWD. On this basis, a standardized platform for PSI reporting and analysis was constructed based on RWD.

Official Title
-----------------
Retrospective Study on Perioperative Safety and Quality Control Based on Real World Data

Conditions
-----------------
Perioperative Complication

Intervention / Treatment
-----------------
* Procedure: Screening with PSI check list


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: perioperative patients with anesthesia electronic records. aged more than 18 years old. Exclusion Criteria: data incomplete data missing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with perioperative safety events<br>Patients with perioperative safety events, including post extubation tracheal intubation, intraoperative cardiac arrest, allergic reactions. | Procedure: Screening with PSI check list<br>* Screening PSI with institutional check list<br>|
| Patients without perioperative safety events<br>Patients without perioperative safety events, including post extubation tracheal intubation, intraoperative cardiac arrest, allergic reactions. | Procedure: Screening with PSI check list<br>* Screening PSI with institutional check list<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of PSI | Occurrence of patient safety incident, including post extubation tracheal intubation, intraoperative cardiac arrest, allergic reactions. | Perioperative period, from the beginning of the surgery to 7 days after the surgery. |
Lymphatic Magnetic Resonance Imaging Abnormalities in Children With Tetralogy of Fallot: A Case-Control Study

Study Overview
=================
Brief Summary
-----------------
This study examines subclinical lymphatic abnormalities in Tetralogy of Fallot patients, utilizing lymphatic magnetic resonance and near-infrared fluorescence imaging.

Official Title
-----------------
Lymphatic Magnetic Resonance Imaging Abnormalities in Children With Tetralogy of Fallot: A Case-Control Study

Conditions
-----------------
Tetralogy of Fallot, Lymphatic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ToF Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ToF<br> | |
| Controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lymphatic abnormalities | MRI assessed lymphatic abnormalities | During scan |